Enoximone

Enoximone
Clinical data

Trade names	Perfan
AHFS/Drugs.com	International Drug Names
Routes of administration	Intravenous
ATC code	C01CE03 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Liver (oxidation)
Biological half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
IUPAC name 4-Methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
CAS Number	77671-31-9^Y
PubChem CID	53708
DrugBank	DB04880^Y
ChemSpider	48492^Y
UNII	C7Z4ITI7L7
KEGG	D04004^Y
ChEMBL	CHEMBL249856^Y
Chemical and physical data
Formula	C₁₂H₁₂N₂O₂S
Molar mass	248.302 g/mol
3D model (Jmol)	Interactive image
Melting point	255 to 258 °C (491 to 496 °F) (decomposes)
SMILES O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
InChI InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)^Y Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N^Y

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.

Prepn: BE 883856 (1980 to Richardson-Merrell); R. A. Schnettler et al., U.S. Patent 4,405,635 (1983 to Merrell-Dow)